3 papers in the library · 135 citations · publishing 2013-2024
Br J Clin Pharmacol January 17, 2024 Hannah Thurgur, Michael T. Lynskey, Anne Katrin Schlag et al. 7 citations
Feasibility of a cannabidiol-dominant cannabis-based medicinal product for the treatment of long COVID symptoms: A single-arm open-label feasibility trial.
J Psychopharmacol August 1, 2022 Victoria Amalie Nygart, Lis Marie Pommerencke, Eline Haijen et al. 73 citations
Background: Over the last two decades, a number of studies have highlighted the potential of psychedelic therapy. However, questions remain to what extend these results translate to naturalistic samples, and how contextual factors and the acute psychedelic experience relate to improvements in affective symptoms following psychedelic experiences outside labs/clinics. The present study sought to...
Journal of Psychoactive Drugs September 1, 2013 Robin Lester Carhart-Harris, David John Nutt 55 citations
A web-based survey was used to consult the opinions of experienced drug users on matters related to drug harms. We identified a rare sample of 93 drug users with personal experience with 11 different illicit drugs that are widely used in the UK. Asked to assess the relative harms of these drugs, they ranked alcohol and tobacco as the most harmful, and three "Class A" drugs (MDMA, LSD, and...